在线国产一区二区_成人黄色片在线观看_国产成人免费_日韩精品免费在线视频_亚洲精品美女久久_欧美一级免费在线观看

China sets more funds for HIV research

Updated: 2011-09-15 07:28

By Shan Juan (China Daily)

  Comments() Print Mail Large Medium  Small 分享按鈕 0

BANGKOK - China invested more than $18 million in HIV vaccine research and development in 2010, becoming the third largest contributor globally, after the United States and the European Union, according to a report endorsed by UNAIDS.

Internationally, HIV vaccine research and development (R&D) funding stood at $859 million last year, $9 million less than 2009, while China increased its spending by nearly $4 million over the same period, said the global report issued jointly by international organizations including AIDS Vaccine Advocacy Coalition (AVAC) and Intentional AIDS Vaccine Initiative.

"The long-term nature of vaccine research will require sustained investments globally and more developing countries like China are expected to shoulder more responsibilities," Kevin Fisher, the coalition's policy director said at the 2011 AIDS Vaccine Conference, which opened on Tuesday.

Unfortunately, overall global funding for HIV R&D has flattened out since 2000 and some early supporters, such as Canada and Sweden, have cut back, said the report. In the EU, a major contributor, funding has declined by 23 per cent since 2007.

In contrast, the Chinese government has pledged to further boost funding for HIV vaccine development by at least 20 percent in five years, according to Shao Yiming, director of the virology and immunology department of the National Center for AIDS/STD Control and Prevention.

Currently, China has four major HIV vaccine candidates under development on the mainland, all financed by the government.

"Compared with many developed countries like the US, which has dozens of HIV vaccine candidates under development, China needs more to have a better chance of success," Shao said.

His team is now waiting for approval from China's drug authorities to enter the second phase of the clinical trial for their HIV vaccine candidate, Tiantan.

Usually a vaccine has to undergo three phases of human trials before being licensed for use, experts said. The first two phases mainly test its safety and the third mainly its efficacy.

By May, 24 HIV vaccine candidates had entered the human trial stages across the world, including Tiantan, which is the only one from China to have reached that point.

Shao urged the Chinese government to regularly increase funding for vaccine development, particularly when some attention has been diverted to new prevention measures with proven efficacy.

"An effective and affordable vaccine is unanimously recognized as the ultimate weapon against HIV/AIDS worldwide," he said.

"The funding and human resources for vaccine R&D in China should be diversified and stakeholders like charities and industry should join in the effort."

Currently, all such studies on the mainland are funded and organized by the government, he said.

Half of the resources come from non-public sectors like pharmaceutical companies and philanthropic organizations, according to Shao.

As well, Kevin Fisher called on the Chinese government to be more transparent and to collaborate with international researchers in HIV vaccine development.

He said the Chinese authorities were usually reluctant to share relevant information, such as the amount of investment, with international stakeholders.

主站蜘蛛池模板: 伊人网视频 | 蜜桃精品一区二区三区 | 国产三级久久 | 久久亚洲国产 | 丰满女人裸体淫交 | 欧美xx孕妇| 69国产精品 | 久操福利视频 | 一个色综合网 | 欧美a一级| 夜夜肉她怀孕h周君彦 | 免费成人小视频 | 在线播放亚洲 | 色影视| xxxx色| 黄色福利视频 | 一区二区高清视频 | 欧美性久久 | 一区二区三区四区在线视频 | 福利网站在线观看 | 亚洲精品一二三区 | 成年人视频网站 | 精品一二三 | 日本三级韩国三级美三级91 | 成人一二区| 国产午夜三级 | 91久久国产精品 | 亚洲成av| 亚洲小视频在线观看 | 欧美专区在线 | 久久久精品免费 | 91手机在线视频 | 成人免费视频观看视频 | 日韩资源在线 | 欧美a级成人淫片免费看 | 久久久三级 | 日本成人小视频 | 久久久久国产一区二区三区 | 精品欧美黑人一区二区三区 | 久久久久久97 | 日韩成人精品 |